On 1 September 2017, Dopharma International B.V. had acquired 65% of the company shares of RIPAC-LABOR and since then, Mrs. Dagmar Köhler-Repp as managing shareholder had further developed RIPAC-LABOR together with Dopharma International B.V.
Already since 2014, Dopharma International B.V. has started to gain extensive experience in the marketing, distribution and production of farm specific vaccines. The company considers this type of prophylaxis to be an important strategic axis in animal health solutions and will consequently continue to invest.
For this reason, Dopharma International B.V. has agreed with Mrs. Dagmar Köhler-Repp to acquire also the remaining shares in RIPAC-LABOR. As a result, Mrs. Dagmar Kohler has decided to terminate her activities at RIPAC-LABOR on 31 July 2021.
RIPAC-LABOR is represented by Mr. Heiko Rüdiger as Managing Director. He joined the company at the end of 2020 and will lead RIPAC-LABOR as an important company in the Dopharma Group.
RIPAC-LABOR will continue to supply and improve these important vaccines in the European market together with the Dopharma Group, ensuring availability for you, our valued customers.
With this important change at RIPAC-LABOR comes further investment in the quality of products and services, as well as for expanded production capacity needed to meet the demands for farm vaccines not only now, but also in the future.
If you have any questions about this announcement, please contact Mr Heiko Rüdiger:
+49 175 4709368